Dmitrij Kollins

Franz Josef Strauß Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 07, 2026

The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency.

The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency.

Journal: Clinical kidney journal

Published: December 16, 2024

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.

Journal: The New England journal of medicine

Published: October 25, 2024

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.

Journal: Kidney international

Published: December 07, 2022

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

Journal: Kidney international reports

Published: November 01, 2022

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.

Journal: Rheumatology (Oxford, England)

Published: November 20, 2019

Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.

Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.

Journal: Arthritis care & research

Published: May 21, 2018

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.

Journal: British journal of clinical pharmacology

Published: July 29, 2016

Urine of patients with acute kidney transplant rejection show high normetanephrine and decreased 2-hydroxyestrogens concentrations.

Urine of patients with acute kidney transplant rejection show high normetanephrine and decreased 2-hydroxyestrogens concentrations.

Journal: Transplantation proceedings

Published: December 04, 2012

Lipoxygenase products in the urine correlate with renal function and body temperature but not with acute transplant rejection.

Lipoxygenase products in the urine correlate with renal function and body temperature but not with acute transplant rejection.

Journal: Lipids

Published: August 01, 2012

Complete recovery after near-fatal multifocal embolization of giant cardiac thrombus: importance of rapid cerebrovascular intervention.

Complete recovery after near-fatal multifocal embolization of giant cardiac thrombus: importance of rapid cerebrovascular intervention.

Journal: European heart journal

Published: July 10, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026